AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

In dem drecksladen

Ja Geil. 1 Tag dabei. 270€ minus... Läuft... 🤦‍♂️🤦‍♂️🤦‍♂️

Wieviel Anteile hast?

2400 Stück

Wäre gerne paar 100 Euro in minus

Weil das auch voll der scheiss laden ist die machen nichts die packen net mal in einem Quartal 10 milonen Umsatz zu.erziehlen

Viel Bewegung und Interesse ist nicht an der Aktie 😂

Diese 1 oder lass es 2 Milliarden sein was die auf dem.konto haben sind in paar Jahren aufgebraucht dann gute Nacht abcellera

Mach wie du denkst ich glaube an den drecks Laden garnicht mehr in 2 oder 3 Jahre wird das Unternehmen Insolvenz gehen die machen kaum Umsätze und den ihre Kosten sind zu hoch

Buy Rating Affirmed for AbCellera Biologics Amid Expanding TCE Program and Strengthened Eli Lilly Collaboration Jason Carr Aug 07, 2024, 01:45 PM BMO Capital analyst Evan Seigerman has maintained their bullish stance on ABCL stock, giving a Buy rating yesterday. Evan Seigerman has given his Buy rating due to a combination of factors that illustrate AbCellera Biologics’s promising future. The expansion of the company’s preclinical T-cell engager (TCE) program, specifically with the CD19xCD3 asset, has been seen as a strategic move, capitalizing on the current market interest in B-cell depleting immunology assets. This forward-looking approach indicates a shift in business priorities towards long-term potential, despite short-term decreases in research revenue, which Seigerman perceives as an investment into a more lucrative development path for AbCellera. Furthermore, Seigerman’s confidence is bolstered by the expanded collaboration between AbCellera and Eli Lilly, which is expected to further the development in critical areas such as immunology, cardiovascular, and neuroscience. This partnership not only demonstrates the pharmaceutical industry’s trust in AbCellera’s antibody platform but also foretells a future of increased collaborative programs and improved deal economics. The validation of AbCellera’s platform by successful antibody treatments like bamlanivimab and bebtelovimab is anticipated to attract even more partner interest, which underpins Seigerman’s optimistic view and justifies the Buy rating. ABCL’s price has also changed dramatically for the past six months – from $5.180 to $2.850, which is a -44.98% drop .

Interessant ist das hier schon... Bin aber mit Canada Unternehmen eher vorsichtig... Deshalb 😉

Bin mal mit 1100 Stück dabei. Ich schau es mir an... Wir werden sehen 🙃

War ausgestiegen. Gesternabend 2900 Stück angekauft an 2,70 $.

Ok. Dann würde mich aber zumindest dein EK interessieren. Liegt vermutlich höher 🤔?

Steven Mah -- Analyst OK. That makes sense. And then, maybe pivoting over to your Viking ArrowMark collaboration. Given the success with Abdera and Invetx, those have worked out well. How is the Viking ArrowMark collaboration going and when should we start to expect to see companies start to launch out of that collaboration? Thank you. Carl Hansen -- Chief Executive Officer We love that collaboration. I would say, it's off to a great start, but we are still in the early innings, right? So we are working with them on program ideas and intend to create companies once we have development candidates. So that's something that's going to take some time to play out and we will let you know when we have something interesting to report. But I do agree that the Abdera example is a terrific example of the value that can be created by finding good ideas and complementary skills and executives and putting that together with the built platform. And we certainly hope to repeat that and we're working hard to make sure that we do. https://www.fool.com/earnings/call-transcripts/2024/08/07/abcellera-biologics-abcl-q2-2024-earnings-call-tra/?source=djc&utm_source=djc&utm_medium=feed&utm_campaign=article&referring_guid=a1695436-f66e-4a57-90ab-e664d98cfd8c&mod=mw_quote_news